Crisis Intervention in Substance Use Disorders: The Synergistic Efforts of Nursing, Pharmacy, and Social Work
DOI:
https://doi.org/10.22399/ijcesen.4793Keywords:
crisis intervention, substance use disorders, interdisciplinary collaboration, nursing role, pharmacy role, social work roleAbstract
Effective crisis intervention in substance use disorders (SUDs) requires an integrated, multidisciplinary approach that leverages the unique expertise of nursing, pharmacy, and social work to address the complex biopsychosocial dimensions of addiction-related emergencies. Nurses provide immediate clinical stabilization, continuous monitoring, and therapeutic engagement, forming a critical human connection during moments of acute vulnerability. Pharmacists contribute specialized knowledge in toxicology, withdrawal management, and the initiation of medication-assisted treatment (MAT), ensuring precise pharmacological intervention. Social workers address the systemic and environmental determinants of crisis by conducting psychosocial assessments, securing resources, and facilitating linkages to ongoing care and recovery support services. The synergy of these professions—guided by shared principles of harm reduction, trauma-informed care, and recovery-oriented systems—transforms acute crises into opportunities for sustainable engagement and healing. Without such collaboration, interventions risk being fragmented and temporary, underscoring the necessity of structured, interdisciplinary models in improving outcomes and reducing the cyclical nature of SUD crises.
References
[1] Volkow ND, Baler RD. Now vs later brain circuits: implications for obesity and addiction. Trends Neurosci 2015;38:345‐52.
[2] Institute for Health Metrics and Evaluation . Smoking – Level 3 risk. Lancet 2020;396:S258‐9.
[3] World Health Organization . Tobacco. Geneva: World Health Organization, 2022.
[4] Institute for Health Metrics and Evaluation . Global smoking prevalence and cigarette consumption 1980‐2012. Seattle: Institute for Health Metrics and Evaluation, 2022.
[5] Degenhardt L, Charlson F, Ferrari A et al. The global burden of disease attributable to alcohol and drug use in 195 countries and territories, 1990‐2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet 2018;5:987‐1012.
[6] Hasin DS, O'Brien CP, Auriacombe M et al. DSM‐5 criteria for substance use disorders: recommendations and rationale. Am J Psychiatry 2013;170:834‐51.
[7] Murray CJL, Aravkin AY, Zheng P et al. Global burden of 87 risk factors in 204 countries and territories, 1990‐2019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet 2020;396:1223‐49.
[8] Volkow ND. The epidemic of fentanyl misuse and overdoses: challenges and strategies. World Psychiatry 2021;20:195‐6.
[9] Volkow ND, Wise RA, Baler R. The dopamine motive system: implications for drug and food addiction. Nat Rev Neurosci 2017;18:741‐52.
[10] Institute for Health Metrics and Evaluation . Drug use disorders – Level 3 cause. www.thelancet.com.
[11] Maiorov VI. The functions of dopamine in operant conditioned reflexes. Neurosci Behav Physiol 2019;49:887‐93.
[12] Reitsma MB, Kendrick PJ, Ababneh E et al. Spatial, temporal, and demographic patterns in prevalence of smoking tobacco use and attributable disease burden in 204 countries and territories, 1990‐2019: a systematic analysis from the Global Burden of Disease Study 2019. Lancet 2021;397:2337‐60.
[13] Vasilenko SA, Evans‐Polce RJ, Lanza ST. Age trends in rates of substance use disorders across ages 18‐90: differences by gender and race/ethnicity. Drug Alcohol Depend 2017;180:260‐4.
[14] Schenk S, Highgate Q. Methylenedioxymethamphetamine (MDMA): serotonergic and dopaminergic mechanisms related to its use and misuse. J Neurochem 2021;157:1714‐24.
[15] Palamar JJ, Ciccarone D, Rutherford C et al. Trends in seizures of powders and pills containing illicit fentanyl in the United States, 2018 through 2021. Drug Alcohol Depend 2022;234:109398.
[16] Han B, Compton WM, Jones CM et al. Methamphetamine use, methamphetamine use disorder, and associated overdose deaths among US adults. JAMA Psychiatry 2021;78:1329‐42.
[17] United Nations . World drug report 2021. New York: United Nations, 2021.
[18] United Nations Office on Drugs and Crime . World drug report – drug market trends: cannabis and opioids. New York: United Nations, 2021.
[19] Ritchie H, Roser M. Opioids, cocaine, cannabis and illicit drugs. ourworldindata.org.
[20] World Health Organization . Global status report on alcohol and health 2018. Geneva: World Health Organization, 2018.
[21] United Nations Office on Drugs and Crime . World drug report – other drug policy issues. New York: United Nations, 2020.
[22] Institute for Health Metrics and Evaluation . Drug use – Level 2 risk. www.thelancet.com.
[23] Volkow ND, Morales M. The brain on drugs: from reward to addiction. Cell 2015;162:712‐25.
[24] Patel V, Chisholm D, Dua T et al. Mental, neurological, and substance use disorders: disease control priorities. Washington: International Bank for Reconstruction and Development/World Bank, 2016.
[25] James SL, Abate D, Abate KH et al. Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990‐2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet 2018;392:1789‐858.
[26] Imtiaz S, Nafeh F, Russell C et al. The impact of the novel coronavirus disease (COVID‐19) pandemic on drug overdose‐related deaths in the United States and Canada: a systematic review of observational studies and analysis of public health surveillance data. Subst Abuse Treat Prev Policy 2021;16:87.
[27] Wise RA. Dopamine and reward: the anhedonia hypothesis 30 years on. Neurotox Res 2008;14:169‐83.
[28] National Center for Health Statistics . Provisional drug overdose death counts. Hyattsville: National Center for Health Statistics, 2022.
[29] American Psychiatric Association . Diagnostic and statistical manual of mental disorders, 5th ed. Arlington: American Psychiatric Association, 2013.
[30] Mitchell MR, Berridge KC, Mahler SV. Endocannabinoid‐enhanced “liking” in nucleus accumbens shell hedonic hotspot requires endogenous opioid signals. Cannabis Cannabinoid Res 2018;3:166‐70.
[31] Volkow ND, Ding YS, Fowler JS et al. Is methylphenidate like cocaine? Studies on their pharmacokinetics and distribution in the human brain. Arch Gen Psychiatry 1995;52:456‐63.
[32] Degenhardt L, Bharat C, Bruno R et al. Concordance between the diagnostic guidelines for alcohol and cannabis use disorders in the draft ICD‐11 and other classification systems: analysis of data from the WHO's World Mental Health Surveys. Addiction 2019;114:534‐52.
[33] Institute for Health Metrics and Evaluation . Alcohol use – Level 2 risk. Lancet 2020;396:S264‐5.
[34] Cruz MT, Bajo M, Schweitzer P et al. Shared mechanisms of alcohol and other drugs. Alcohol Res Health 2008;31:137‐47.
[35] Olfson M, Crystal S, Wall MM et al. Causes of death after nonfatal opioid overdose. JAMA Psychiatry 2018;75:820‐7.
[36] Franco S, Olfson M, Wall MM et al. Shared and specific associations of substance use disorders on adverse outcomes: a national prospective study. Drug Alcohol Depend 2019;1:212‐9.
[37] Blanco C, Wall MM, Hoertel N et al. Psychiatric disorders and risk for multiple adverse outcomes: a national prospective study. Mol Psychiatry 2021;26:907‐16.
[38] UK Office for National Statistics . Deaths related to drug poisoning in England and Wales: 2021 registrations. London: UK Office for National Statistics, 2021.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2024 International Journal of Computational and Experimental Science and Engineering
This work is licensed under a Creative Commons Attribution 4.0 International License.
